logo
logo

Iterative Scopes Announces $150 Million Series B To Advance Ai-Driven Precision Medicine For Gastroenterology

Iterative Scopes Announces $150 Million Series B To Advance Ai-Driven Precision Medicine For Gastroenterology

01/19/22, 1:00 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgcambridge
Money raised
$150 million
Round Type
series b
Iterative Scopes, a pioneer in the development of precision-based gastrointestinal (GI) disease technologies and software, announced today that it has raised $150 million in Series B financing to accelerate development of its core algorithmic innovations that are designed to transform gastroenterology care for patients. The round was co-led by Insight Partners and Clearlake Capital Group, L.P. (together with certain of its affiliates, “Clearlake”), as well as by returning investors Obvious Ventures, Johnson and Johnson Innovation-JJDC Inc., Eli Lilly, Breyer Capital and other industry and financial leaders.

Company Info

Company
Iterative Scopes
Location
cambridge, maryland, united states
Additional Info
Iterative Scopes is fast becoming the leader in computational gastroenterology through its pioneering application of powerful, proprietary artificial intelligence tools to the practice of gastroenterology and drug development. It is taking a multi-tiered approach to tackling the challenges of endoscopic-driven disease management. The initial products and services offered by Iterative Scopes aim to identify and standardize relevant insights from endoscopic videos used for detection and monitoring of colorectal cancers and inflammatory bowel disease (IBD). Longer term, the company is building predictive models that can augment clinical trial endpoints and individualized therapeutic selection processes, with the potential to create novel endpoints that are better predictors of therapeutic response and disease outcomes. Spun out of MIT in 2017, the team is based in Cambridge, Massachusetts. For more information, visit www.iterativescopes.com.